Stockscreener 앱 받기
1.21
2.54%
0.03
Ernexa Therapeutics Inc 주식(ERNA)의 최신 뉴스
Can Ernexa Therapeutics Inc continue delivering strong returnsPortfolio Gains Report & Reliable Intraday Trade Plans - baoquankhu1.vn
Volume Report: What is TTGTs revenue forecastTrade Risk Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Ernexa Therapeutics (NASDAQ:ERNA) vs. Inotiv (NASDAQ:NOTV) Critical Review - Defense World
Market Recap: Can Ernexa Therapeutics Inc continue delivering strong returnsJuly 2025 PostEarnings & Low Risk High Reward Ideas - baoquankhu1.vn
Aug PostEarnings: Will Ernexa Therapeutics Inc. stock recover faster than peersMarket Performance Report & Weekly Top Performers Watchlists - Bộ Nội Vụ
Bull Run: How institutional buying supports Ernexa Therapeutics Inc stockJuly 2025 Trends & Low Drawdown Momentum Trade Ideas - Bộ Nội Vụ
Is Ernexa Therapeutics Inc. stock trading at a premium valuationJuly 2025 Pullbacks & Technical Pattern Alert System - Улправда
How Ernexa Therapeutics Inc. stock reacts to inflationary pressures2025 Price Momentum & Daily Price Action Insights - Улправда
How Ernexa Therapeutics Inc. stock compares to industry benchmarksCPI Data & Low Risk High Win Rate Picks - Улправда
Ernexa’s stem cell therapy could soon enter ovarian cancer trials - Rare Cancer News
Ernexa Therapeutics announces successful pre-Ind FDA meeting - marketscreener.com
Ernexa receives FDA alignment for ovarian cancer cell therapy By Investing.com - Investing.com Canada
Ernexa Therapeutics Advances Ovarian Cancer Treatment Toward First-in-Human Trial After FDA Meeting - Quiver Quantitative
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-In-Human Trial in Ovarian Cancer - marketscreener.com
Will Ernexa Therapeutics Inc. stock pay special dividends2026 world cup usa national team group stage key players possession football group prediction preview - Улправда
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer - Yahoo Finance
Published on: 2026-01-02 17:34:55 - Bộ Nội Vụ
Is Ernexa Therapeutics Inc. stock attractive for growth ETFsEarnings Growth Report & Technical Confirmation Trade Alerts - DonanımHaber
How Ernexa Therapeutics Inc. stock performs in rate cut cyclesQuarterly Earnings Report & Expert Curated Trade Setups - DonanımHaber
Ernexa Therapeutics (NASDAQ:ERNA) Stock Price Down 5.1% – Here’s What Happened - Defense World
Ernexa Therapeutics Earnings Notes - Trefis
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Ernexa Therapeutics stock falls after ASH meeting presentation By Investing.com - Investing.com Australia
Ernexa Therapeutics stock falls after ASH meeting presentation - Investing.com
Ernexa reports promising preclinical data for cancer cell therapy By Investing.com - Investing.com Australia
Ernexa Therapeutics Presents New Preclinical Data on ERNA-101 at ASH Annual Meeting Highlighting Innovative Cell Therapy Potential to Combat Cancer - Quiver Quantitative
Ernexa reports promising preclinical data for cancer cell therapy - Investing.com
Ernexa Therapeutics Presents New Preclinical Data at - GlobeNewswire
Ernexa Therapeutics (ERNA) Stock Analysis Report | Financials & Insights - Benzinga
With Ernexa Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
Can Ernexa Therapeutics Stock Recover If Markets Fall? - Trefis
Ernexa Therapeutics Inc. (ERNA) 5.2% in After-hours: Strong Presentation Initiative - Stocks Telegraph
Ernexa Therapeutics announces oral presentation at the 67th American Society of Hematology - marketscreener.com
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Can Ernexa Therapeutics Inc. stock hit analyst price targetsWeekly Stock Recap & AI Powered Trade Plan Recommendations - Newser
How Ernexa Therapeutics Inc. stock compares to market leadersTrade Analysis Summary & Verified Stock Trade Ideas - Newser
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG - markets.businessinsider.com
Ernexa Therapeutics appoints oncologist Dr. Winer to advisory board By Investing.com - Investing.com Australia
Ernexa Therapeutics appoints oncologist Dr. Winer to advisory board - Investing.com
Ernexa Therapeutics Appoints Dr. Ira S. Winer to Scientific and Medical Advisory Board - Quiver Quantitative
Profit Review: How Ernexa Therapeutics Inc. stock compares to industry benchmarks2025 Historical Comparison & Fast Moving Trade Plans - BỘ NỘI VỤ
Contrasting Ernexa Therapeutics (NASDAQ:ERNA) & KalVista Pharmaceuticals (NASDAQ:KALV) - Defense World
How Ernexa Therapeutics Inc. stock reacts to oil pricesJuly 2025 Action & Fast Momentum Stock Entry Tips - newser.com
How to monitor Ernexa Therapeutics Inc. with trend dashboardsTrade Entry Summary & Low Risk Entry Point Tips - newser.com
Ernexa Therapeutics Inc. stock chart pattern explained2025 Market Outlook & Verified Momentum Stock Alerts - newser.com
Sector ETF performance correlation with Ernexa Therapeutics Inc.Gap Down & Free AI Powered Buy and Sell Recommendations - newser.com
Is it too late to sell Ernexa Therapeutics Inc.Earnings Risk Report & AI Enhanced Trading Alerts - newser.com
Will Ernexa Therapeutics Inc. bounce back from current supportGold Moves & Real-Time Stock Entry Alerts - newser.com
Why Ernexa Therapeutics Inc. stock could see breakout soonTrend Reversal & Weekly Setup with High ROI Potential - newser.com
Analyzing drawdowns of Ernexa Therapeutics Inc. with statistical toolsGap Down & Long-Term Safe Investment Plans - newser.com
Will Ernexa Therapeutics Inc. stock benefit from automationEntry Point & AI Powered Buy/Sell Recommendations - newser.com
Should I hold or sell Ernexa Therapeutics Inc. stock in 2025Forecast Cut & Free Growth Oriented Trading Recommendations - newser.com
4.73%
0.92%
자본화:
|
볼륨(24시간):